SCHEMBL3762387

SCHEMBL3762387

C#CCN(C)S(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3ccc(C(C)C)cc3)c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CNR1 P21554 1/20 0.42
MCL1 Q07820 1/20 0.42
PTGER4 P35408 6/20 0.41
NR3C1 P04150 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
IDH1 O75874 1/20 0.39
F10 P00742 1/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760152 0.89 PTGER4 (0.44) KDM4EMEN1KMT2ACNR1MCL1
SCHEMBL3754165 0.86 ALDH1A1 (0.42) KDM4EMEN1KMT2AMCL1PTGER4
SCHEMBL3430253 0.84 KDM4E (0.49) KDM4EMEN1KMT2ACNR1MCL1
SCHEMBL3426970 0.84 KDM4E (0.49) KDM4EMEN1KMT2ACNR1MCL1
SCHEMBL3430845 0.84 KMT2A (0.45) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL13671954 0.83 IDH1 (0.54) KDM4EMEN1KMT2ACNR1MCL1
SCHEMBL3432164 0.80 PTGER4 (0.51) KMT2ACNR1PTGER4NR3C1HDAC3
SCHEMBL3428243 0.80 PTGER4 (0.52) CNR1PTGER4NR3C1F10NPC1
SCHEMBL12996417 0.79 PTGER4 (0.49) CNR1PTGER4NR3C1HDAC3HDAC1
SCHEMBL3755332 0.78 KDM4E (0.54) KDM4EMEN1KMT2ACNR1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 KDM4E 1965/4885MEN1 3958/4885KMT2A 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.